DBV Technologies (DBVT)
(Delayed Data from NSDQ)
$0.68 USD
-0.01 (-1.09%)
Updated Apr 26, 2024 03:57 PM ET
After-Market: $0.68 0.00 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DBVT 0.68 -0.01(-1.09%)
Will DBVT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DBVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DBVT
Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
DBVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study
Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
Other News for DBVT
Combined General Meeting of May 16, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes